Divis' Laboratories Share Price (DIVISLAB)
as on
| Source : NSE
Divis' Laboratories Stock Performance
as on August 20, 2025 at 4:01 PM IST
Day's Low
Day's High
₹5,952.5₹6,096
0.87%
Downside
1.52%
Upside
52 Week's Low
52 Week's High
₹4,615.55₹7,071.523.14%
Downside
17.76%
Upside
| Market Stats | |
| Previous Close | ₹6,079.50 |
| Open | ₹6,084.00 |
| Volume | 5.44L |
| Upper Circuit | ₹6,687.00 |
| Lower Circuit | ₹5,472.00 |
| Day's Low | ₹5,952.5 |
| Day's High | ₹6,096 |
| 52 Week Low | ₹4,615.55 |
| 52 Week High | ₹7,071.5 |
| Returns % | |
| 1 Month Return | -9.1 % |
| 3 Month Return | -5.78 % |
| 1 Year Return | + 28.72 % |
| 3 Year Return | + 69.79 % |
| 5 Year Return | + 90.62 % |
Divis' Laboratories Stock Fundamentals & Key Indicators
Check Divis' Laboratories market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹1,61,391.62 Cr
Return on Equity (ROE)
15.57
PE Ratio (TTM)
70.02
Return on capital employed (ROCE)
20.63
Industry PE ratio
43.53
Beta (LTM)
0.78
P/B Ratio
10.27
Dividend Yield
0.52
PEG Ratio
2.95
Quarterly Earnings Growth YOY
26.74
EPS (TTM)
82.68
Sector
Pharmaceuticals
Book Value
564.87
Technical Analysis
Bearish
View Technical Analysis
Divis' Laboratories Stock's Interest Amongst Investors
Divis' Laboratories Stock Valuation
Track how Divis' Laboratories P/E has moved over time to understand its valuation trends.
Divis' Laboratories in the last 5 years
Lowest (28.97x)
November 21, 2022
Industry (43.53x)
August 19, 2025
Today (70.02x)
August 19, 2025
Highest (90.48x)
December 4, 2024
Today’s Price to Earnings Ratio: 70.02x
Divis' Laboratories Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Divis' Laboratories.
based on 29 analysts
35.71%
Buy
25.00%
Hold
39.29%
Sell
39.29% of analysts recommend a 'HOLD' rating for Divis' Laboratories. Average target price of ₹6384.14
Source: S&P Global Market Intelligence
Divis' Laboratories Share Price Target
Get share price movements and forecasts by analysts on Divis' Laboratories.
Divis' Laboratories price forecast by 29 analysts
Upside of5.01%
High
₹7750
Target
₹6384.14
Low
₹4250
Divis' Laboratories target price ₹6384.14, a slight upside of 5.01% compared to current price of ₹6005. According to 29 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Divis' Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:35.47%
Forecast
Actual
Including amortisation and stock based compensations
Divis' Laboratories EPS growth forecast
EPS estimate Q1, FY2027:46.52%
Forecast
Actual
Source: S&P Global Market Intelligence
Divis Laboratories Ltd Financial Results
Get the annual and quarterly financial summary of Divis Laboratories Ltd, including revenue, profit, loss and more.
Divis' Laboratories Earnings and Dividends
View detailed summary of the earnings and dividend history of Divis' Laboratories.
Divis Laboratories Ltd Earnings Results
Divis Laboratories Ltd’s net profit jumped 26.74% since last year same period to ₹545.00Cr in the Q1 2025-2026. On a quarterly growth basis, Divis Laboratories Ltd has generated -17.67% fall in its net profits since last 3-months.
Read More about Earnings ResultsDivis Laboratories Ltd Dividends May,2025
In the quarter ending March 2025, Divis Laboratories Ltd has declared dividend of ₹30.00 per share on 17 May 2025 - translating a dividend yield of 0.97%.
Read More about Dividends
Indices Featuring Divis' Laboratories Stock
Check stock indices that include Divis' Laboratories.
Divis' Laboratories Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Divis' Laboratories.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.89% | ||
| Foreign Institutions | 19.74% | 9.60 | |
| Mutual Funds | 13.31% | 3.78 | |
| Retail Investors | 9.32% | ||
| Others | 5.74% |
Divis Laboratories Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Divis' Laboratories with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 1,61,391.62 | 18.12% | 0.50 | 2,191 | 9,360 | |
| BUY | 1,23,581.19 | 31.89% | 0.66 | 1,911 | 11,516 | |
| BUY | 48,645.42 | -1.54% | 0.78 | 1,429 | 15,261 | |
| HOLD | 32,036.89 | 1.37% | 0.53 | 698 | 5,616 | |
| BUY | 1,25,113.03 | 20.62% | 0.51 | 5,291 | 27,547 |
Divis' Laboratories News & Key Events
Latest news and events in one place to help you make informed investing decisions in Divis' Laboratories.
Divis Laboratories Faces Mixed Analyst Reactions Post Q1 Results - 07 Aug, 2025
Divis Laboratories reported strong Q1 growth, but missed analyst estimates, leading to mixed reactions and target price revisions from various brokerages. Operational costs and pressures in the generics segment remain concerns, prompting some analysts to lower EPS estimates. Despite this, some brokerages maintain positive outlooks based on expected margin improvements and growth in custom synthesis contracts.Divis Laboratories Reports Q1 Results Below Expectations - 06 Aug, 2025
Divis Laboratories announced Q1 FY26 results, reporting a net profit of ₹545 crore, missing estimates. Revenue rose 13.8% YoY but fell 6.79% QoQ, reflecting pricing pressures in the generics market.Divis Laboratories Faces Revenue Risk from Patent Loss - 14 Jul, 2025
Divis Laboratories shares fell after MSN Laboratories won a patent lawsuit against Novartis' Entresto, potentially impacting Divis' revenue by up to 20%. Analysts warn of a significant earnings decline due to this development.Divis Laboratories Reports Strong Earnings and Bullish Momentum - 10 Jul, 2025
Divis Laboratories demonstrates robust performance with FY25 revenue of Rs 9,360 crore and a net profit of Rs 2,191 crore. The stock shows strong bullish momentum, trading above key moving averages, with a target price of ₹7,125–₹7,140.
Insights on Divis Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 18.01% to 19.74% in Jun 2025 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 1 year, DIVISLAB stock has moved up by 28.7%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.83% to 13.31% in Jun 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.89% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 139.2% return, outperforming this stock by 69.4%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 662.0 Cr → 545.0 Cr (in ₹), with an average decrease of 17.7% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 2.67K Cr → 2.52K Cr (in ₹), with an average decrease of 5.3% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.39% to 9.32% in Jun 2025 quarter
About Divis Laboratories Ltd
Divis Laboratories Ltd's top products include APIs and intermediates for anti-infectives, cardiovascular, central nervous system, anti-diabetics, gastro-intestinal and anti-inflammatory treatments. The company is also a leader in the manufacture of custom synthesis and process development services for the global pharmaceutical industry.
Divis Laboratories Ltd is the proud owner of several popular brands, including Divis Life, Divis Pharma and Divis Health. Divis Life offers a range of health and wellness products, while Divis Pharma provides a wide range of APIs, intermediates and custom synthesis services.
Revenue: ₹2,410.00Cr as on June 2025 (Q1 FY26)
Net Profit: ₹545.00Cr as on June 2025 (Q1 FY26)
Listing date: 12 Mar, 2003
Chairperson Name: Ramesh B V Nimmagadda
| Organisation | Divis Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | Ramesh B V Nimmagadda |
| E-voting on shares | Click here to vote |
Mutual Funds that own Divis' Laboratories Stock
Check out the Mutual Funds with significant holdings in Divis' Laboratories.
FAQs
What is Divis' Laboratories share price today?
Divis' Laboratories share price today stands at ₹6005, Open: ₹6084, Previous Close: ₹6079.5, High: ₹6096, Low: ₹5952.5, 52 Week High: ₹7071.5, 52 Week Low: ₹4615.55 as on .
How to buy Divis' Laboratories shares ?
To buy Divis' Laboratories shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for DIVISLAB or Divis Laboratories Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Divis' Laboratories shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Divis' Laboratories?
Today's traded volume of Divis' Laboratories is 5.44L. Which means that 5.44L shares of Divis' Laboratories were bought and sold on the stock market during today's trading session.
What is Divis' Laboratories's market cap today?
Today's market capitalisation of Divis' Laboratories is ₹1,61,391.62 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Divis' Laboratories?
Divis' Laboratories’s 52 week high is ₹7071.5 and 52 week low is ₹4615.55. The current share price of Divis' Laboratories is ₹6005, which is -15.08% down from its 52 week high and 30.10% up from its 52 week low.